alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › plasma-biomarkers

plasma-biomarkers

12 studies tagged plasma-biomarkers, dated 2013-12-07 to 2025-08-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients 2025-08-01
  2. Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice 2025-03-01
  3. Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use 2025-01-14

Studies

12 studies carry this tag.

Date range

2013 to 2025

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 5
  • Alzheimer's research & therapy 1
  • CPT: pharmacometrics & systems pharmacology 1
  • International journal of geriatric psychiatry 1
  • Journal of affective disorders 1

8 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of neurochemistry 2025-08-01 Biomarkers

    Alzheimer's disease (AD) is characterized by brain protein depositions, impaired synaptic transmission, and progressive cognitive decline.

  2. Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-03-01 Biomarkers

    Plasma biomarkers for Alzheimer's disease (AD), such as plasma phosphorylated (p)-tau217, offer a more accessible means of testing for the presence of AD pathology compared to cerebrospinal fluid (CSF) or positron emission tomography (PET) methods.

  3. Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. The journal of prevention of Alzheimer's disease 2025-01-14 Biomarkers

    As novel, anti-amyloid therapies have become more widely available, access to timely and accurate diagnosis has become integral to ensuring optimal treatment of patients with early-stage Alzheimer's disease (AD).

  4. Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's research & therapy 2024-07-03 Biomarkers

    Amyloid, tau, neurodegeneration and neuroinflammation plasma biomarkers are modified in DLB, albeit with moderate diagnosis performance.

  5. Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-05-16 Biomarkers

    These relatively non-invasive tests may be beneficial for clinical screening after replication in other populations and validation through neuroimaging or cerebrospinal fluid analysis.

  6. Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multi-ethnic Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP) cohort

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-01-06 Biomarkers

    Elevated levels of AD biomarker p-tau181/Aβ42, by itself or combined with a low Aβ42/Aβ40 level, predicts clinically diagnosed AD.

  7. Neuropsychiatric symptoms in Alzheimer's continuum and their association with plasma biomarkers

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of affective disorders 2023-12-29 Biomarkers

    This study supported neuropsychiatric symptoms as early manifestations of preclinical Alzheimer's disease, and suggested plasma NfL to be a potential biomarker for detecting neuropsychiatric symptoms in Alzheimer's continuum.

  8. Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-12-17 Biomarkers

    GFAP, NfL, and p-tau181 are valuable predictors of cognition and function across common neurodegenerative diseases, and may be useful in specialized clinics and clinical trials.

  9. Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-07-28 Biomarkers

    This study supports that PET- and CSF-related A/T/N profiles can be used to predict accurately the stages of AD neuropathology.

  10. Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. CPT: pharmacometrics & systems pharmacology 2022-09-27 Biomarkers

    Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer.

  11. Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer's Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of clinical medicine 2019-11-06 Biomarkers

    Brain degeneration in patients with Alzheimer's disease (AD) results from the accumulation of pathological amyloid- (Aβ) plaques and tau protein tangles, leading to altered plasma levels of biomarkers.

  12. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. International journal of geriatric psychiatry 2013-12-07 Biomarkers

    The plasma Aβ40 biomarker was able to distinguish between AD and NC groups.

All topic tags with their study counts